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ABSTRACT 
 
Renal control of systemic phosphate homeostasis is critical as evident 
from inborn and acquired diseases causing renal phosphate wasting. At least 
three transport proteins are responsible for renal phosphate reabsorption: NAPI-
IIa (SLC34A1), NAPI-IIc (SLC34A3), and PIT-2 (SLC20A2). These transporters 
are highly regulated by various cellular mechanisms and factors including acid-
base status, electrolyte balance, and hormones such as dopamine, 
glucocorticoids, growth factors, vitamin D3, parathyroid hormone, and FGF23. 
Whether renal phosphate wasting is caused by inactivating mutations in the 
NAPI-IIa transporter is controversial. Mutations in the NAPI-IIc transporter cause 
hereditary hypophosphatemic rickets with hypercalciuria. Besides the primary 
inherited defects there are also inherited defects in major regulators of phosphate 
homeostasis that lead to alterations in phosphate handling. Autosomal dominant 
hypophosphatemic rickets is due to FGF23 mutations leading to resistance 
against its own degradation. Similarly, inactivating mutations in the PHEX gene,  
which causes FGF23 inactivation, cause X-linked hypophosphatemia due to 
renal phosphate losses. In contrast, mutations in GALNT3, responsible for O-
glycosylation of FGF23, or in klotho (KL), a cofactor for FGF23 signaling result in 
hyperphosphatemia. Acquired syndromes of renal phosphate wasting, 
hypophosphatemia, and osteomalacia (tumor-associated osteomalacia) can be 
due to the excessive synthesis or release of phosphaturic factors (FGF23, FGF-
7, MEPE, sFRP4) from mesenchymal tumors.   
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INTRODUCTION 
 
About 85 % of total phosphate is deposited in bone and about 10 % in soft 
tissues, the remaining 2-3 % is found in serum, constituting a freely 
exchangeable and tightly regulated phosphate pool. Serum phosphate levels in 
adults are maintained in a narrow range of about 0.8 – 1.45 mmol/l (2.4 – 4.5 
mg/dl).Deviations as found in patients with hypophosphatemia or 
hyperphosphatemia can cause severe disturbances of cellular and organ function 
such ATP depletion, rickets, osteomalacia, anemia, or excessive tissue 
calcifications, nephrolithiasis, arteriosclerosis and increased risk of 
cardiovascular morbidity and mortality [1-3].  
Phosphate homeostasis is the product of intestinal uptake of phosphate 
(in the range of 0.9 – 1 g/day) and reabsorption of phosphate from urine (in the 
range of 60-80 %). Both intestinal uptake and renal reabsorption are mediated by 
sodium-dependent phosphate cotransporters (Na+/Pi-cotransporters) belonging 
to the SLC20 and SLC34 gene families of solute carriers [4-5]. Their activity and 
expression is tightly regulated by a large variety of hormones and metabolic 
factors adjusting uptake and excretion to short and long-term body requirements. 
Inborn errors are caused by mutations in phosphate transporters and in several 
genes that encode factors directly and indirectly involved in their regulation. The 
identification of these genes and elucidation of their functions have greatly 
contributed to our present understanding how phosphate homeostasis is 
achieved. This review will give a brief overview over physiological function and 
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regulation of renal phosphate transporters. For more extensive reviews the 
reader is referred to a number of recent reviews and book chapters [5-9]. The 
second part of this review will discuss mutations in several genes that directly or 
indirectly participate in (renal) control of phosphate balance. 
 
General aspects of renal phosphate handling 
About 80 % of filtered phosphate is reabsorbed from urine under normal 
dietary phosphate intake by the earlier convoluted parts of the proximal tubule of 
mostly juxtamedullary nephrons [4]. Phosphate absorption is mediated by 
sodium-dependent cotransporters for inorganic phosphate (Pi) located in the 
brush border membrane.  
 Three members of the type II Na+/dependent phosphate cotransporter 
family have been identified and classified in the SLC34 solute carrier gene family 
[4]. SLC34A1 ( NAPI-IIa) is predominantly expressed in kidney mediating about 
70 – 80 % of overall phosphate reabsorption as suggested by a Slc34a1 deficient 
mouse model [10]. Another member of this family, SLC34A3 ( NAPI-IIc), is also 
almost exclusively found in kidney [11]. SLC34A2 ( NAPI-IIb) is mostly expressed 
in small intestine and in a number of other organs including testis, lung, liver, and 
lactating mammary glands [12].  
 
Also sodium-dependent phosphate transporters from the SLC20 family are 
expressed in the kidney. PIT-2 (SLC20A2) is localized in the brush border 
membrane of the proximal tubule whereas the exact site of expression of PIT-1 in 
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kidney is unclear [13]. PIT-2 is widely expressed in most tissues. Its exact role in 
renal phosphate reabsorption has not been clarified but simultaneous genetic 
deletion of NaPi-IIa and NaPi-IIc in mice reduced renal phosphate reabsorption 
by more than 90 % suggesting that its contribution to overall phosphate 
reabsorption may be minor [14]. PIT-2 is regulated by dietary phosphate intake, 
acid-base status, and PTH [15-16]. Mutations in  PIT-2 have been described in 
patients with idiopathic basal ganglia calcification  [17]. 
 
SLC34A1 (NaPi-IIa) and SLC34A3 (NaPi-IIc) 
The human SLC34A1 gene lies on chromosome 5q35 [18], is about 13 kb 
in length and consists of 13 exons and 12 introns [19].  Recently a model for the 
protein structure of NAPI-IIa was suggested based on homology modeling and 
detailed structure-function studies [20]. 
 
The human SLC34A3 gene spans about 5 kb containing 13 exons and lies 
on chromosome 9q34 [21-22]. Human NAPI-IIc contains 599 amino acids [21-
22]. NaPi-IIc expression in mouse is stimulated in response to low dietary 
phosphate intake [23]. Also dietary Pi-responsive elements (potential TFE-3 
binding sites) are located at -1846 and -1822 [23].  
 
The transport functions of SLC34A transporters and their structure-
function relationship have been extensively studied elucidating important features 
such as cotransport mode, electrogenicity or voltage and pH-dependency [4]. 
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Collectively these data demonstrate that NAPI-IIa transports three sodium ions 
together with one divalent phosphate ion (HPO42-) per transport cycle. This 
transport mode is electrogenic [24-25]. The transporter homodimerizes but the 
functional unit is a monomer [26-27]. The type IIc cotransporter transports only 2 
sodium ions per phosphate and is electroneutral indicating that divalent 
phosphate is its preferred substrate [28].  
 
Regulation of renal phosphate reabsorption   
 A variety of factors affects renal phosphate handling as listed in table 1 [4, 
29].  Alterations in the number of phosphate transporter molecules in the brush 
border membrane represent the main mechanism leading to changes in urinary 
phosphate excretion [29]. The cellular and molecular mechanisms by which 
NaPi-IIa and NaPi-IIc are regulated have been extensively studied for PTH and 
changes in dietary phosphate intake (for review: [4-5]).  
 
 PTH rapidly induces phosphaturia within minutes by decreasing apical 
phosphate transport activity. Activation of PLC by apical PTH receptors leads to 
protein kinase C dependent stimulation of ERK1/2 kinases and internalization of 
NaPi-IIa [29-31]. NaPi-IIa, apical PTH receptors, and PLCβ1 are organized in a 
macromolecular complex via the PDZ-scaffold protein NHERF1 (NHE regulating 
factor 1) [32-34]. In contrast, basolateral PTH receptors are linked to adenylate 
cyclase, protein kinase A (PKA) and ERK1/2 [31]. NaPi-IIa is not phosphorylated 
but dissociates from NHERF1 which is phosphorylated in response to PTH [35-
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36]. A similar mechanism has been proposed for FGF23- and dopamine-induced 
endocytosis of NaPi-IIa [4]. 
The regulation of renal phosphate reabsorption by FGF23 is mediated by 
several mechanisms: FGF23 reduces circulating levels of active 1,25(OH)2 
vitamin D3 by reducing expression of the activating enzyme CYP27B1 and by 
increasing expression the inactivating enzyme CYP24A1 [37]. Lower active 
vitamin D3 reduces the stimulation of renal and intestinal phosphate 
(re)absorption. Moreover, renal phosphate reabsorption is directly reduced by 
FGF23 through downregulation of NaPiIIa and NaPiIIc. Two alternative but not 
exclusive pathways have been proposed. FGF23 binds to FGF1c receptors in the 
distal convoluted tubule, the main site of klotho expression in kidney, leads to 
ERK1/2 phosphorylation and the distal convoluted tubule then signals to the 
proximal tubule to internalize NaPi-IIa and NaPi-IIc [38]. Alternatively, FGF23 
may bind to FGF23 receptors in the proximal tubule and lead to phosphorylation 
of NHERF1 via Sgk1 [39]. Also, a direct regulation of NaPiIIa activity by klotho 
without FGF23 has been demonstrated where klotho causes cleavage and 
inactivation of NaPi-IIa in the brush border membrane and subsequent 
internalization [40]. 
  
An acute reduction in NaPi-IIa transporters is mediated by the internalization 
from the apical brush border membrane via the same route as receptor-mediated 
endocytosis, requiring megalin and involving clathrin-coated vesicles and early 
endosomes [41-42]. Consequently, NaPi-IIa is routed to lysosomes for 
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degradation [43-44]. The regulation of NaPi-IIc has been studied in less detail: in 
response or high phosphate NaPi-IIc downregulation occurs but is slower than 
for NaPi-IIa [16, 45].  
 
 Renal phosphate reabsorption closely matches dietary phosphate intake 
being high during dietary phosphate restriction and decreasing with high 
phosphate intake [11, 46-48]. In animals lacking PTH and/or 1,25 (OH)2-vitamin 
D3 the adaptive response of NaPi-IIa and NaPi-IIc is partially preserved indicating 
that other factors may be responsible for sensing and mediating changes in 
dietary phosphate intake [49-51].  
 
 
PRIMARY INHERITED DEFECTS IN RENAL PHOSPHATE HANDLING 
SLC34A1 (NAPI-IIa): hypophosphatemic nephrolithiasis/osteoporosis-1 
(NPHLOP1) and Fanconi renotubular syndrome-2 (FRTS2) 
 Two reports addressed patients with mutations in the SLC34A1/NAPI-IIa 
gene. In the first report, two patients with urolithiasis or bone demineralization 
and persistent idiopathic hypophosphatemia with lower maximal renal phosphate 
reabsorption (TmP/GFR) were presented [52].  Single nucleotide changes 
resulting in missense mutations (A48F and V147M) were detected. These 
mutations were found only on one allele per patient suggesting a dominant effect 
[52]. Expression of the mutant NAPI-IIa transporters in oocytes was showed 
reduced phosphate transport  activity, a dominant negative effect on wildtype 
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NAPI-IIa cotransporters, and reduced affinity for phosphate [52]. However, these 
data were controversially discussed. SLC34A1 mutations were not confirmed in 
other kindreds with similar symptoms, relatives of patients had not been 
genetically investigated, and the expression assay showed only low expression 
even for the wildtype transporter rendering a kinetic analysis very difficult. 
Moreover, expression of the reported mutant NAPI-IIa cotransporters in Xenopus 
oocytes and the renal OK cell line did not show any evidence for altered 
subcellular localization, levels of expression, or reduced substrate affinity [53], 
but showed a  lower transport activity.. Yet,  this decrease cannot fully explain 
the massive phosphaturia observed. Therefore, it was suggested that the 
nucleotide changes may represent only polymorphisms. A similar conclusion was 
derived from  screening a large numbers of pedigrees of calcium stone formers 
with low TmP/GFR [54]. Even though a number of mutations including an N-
terminal deletion of 7 amino acids (91del7) in the NAPI-IIa gene were found, no 
correlation with the clinical phenotype could be established. Two of the mutations 
had lower phosphate transport activity after expression in Xenopus oocytes most 
likely due to decreased membrane abundance. However, the reduction in 
transport rates was mild and importantly, only one allele was found to be mutated 
in stone forming patients. The interpretation that these mutations may represent 
rather relatively common polymorphisms was further supported by the fact that 
these gene alterations were found also in several subjects with normal renal 
phosphate excretion. Thus, polymorphisms in the NAPI-IIa gene may be 
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relatively common and their relevance for renal phosphate handling may require 
further clarification. 
A second report described siblings from a consanginous Arab Israeli 
family with hypophosphatemic rickets, multiple fractures and stunted growth [55]. 
The presence of a Fanconi-like syndrome was suggested, but hallmarks of a 
generalized proximal tubule dysfunction are not evident from data reported. The 
patients suffered from hypercalciuria due to elevated serum 1,25(OH)2D3 levels. 
Hypophosphatemia was refractory to vitamin D therapy. Genetic analysis 
detected a homozygous in-frame duplication of 21 base pairs leading to insertion 
of seven additional amino acids at position G154-V160. Heterozygous carriers of 
the mutation were clinically normal suggesting that the mutation did not exert a 
dominant negative effect. Expression of the mutant protein in Xenopus oocytes 
abolished all phosphate-induced currents whereas expression in renal OK cells 
indicated failure of the mutant protein to reach the plasma membrane. 
Thus, homozygous mutations in SLC34A1 may be responsible for renal 
phosphate wasting but whether this is only the case for this specific mutation and 
may be due to toxic effects of the mutant protein for proximal tubule functions or 
whether mutations in this phosphate transporter can provide evidence for the 
biological and clinical importance in human kidney function remains to be 
established.   
 
SLC34A3 (NAPI-IIc): hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH) 
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Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)(OMIM 
#241530) is caused by mutations in the SLC34A3 gene encoding for NAPI-IIc 
[21-22]. The disease was first described in a Bedouin family [56] and is 
characterized by renal phosphate wasting causing hypophosphatemia and 
secondary rickets, with elevated serum alkaline phosphatase. Serum levels of 
1,25-(OH2)-vitamin D3 are high, PTH and FGF23 are low, resulting in enhanced 
intestinal calcium absorption and subsequent renal excretion (hypercalciuria) 
promoting nephrolithiasis or nephrocalcinosis in some patients [21-22, 56-57]. 
Long-term phosphate supplementation appears to reverse the clinical and 
biochemical abnormalities in HHRH.  
The SLC34A3 gene is localized on chromosome 9q34. Observed 
mutations in HHRH include frame shifts in the open reading frame with 
subsequent translation of sequences unrelated to NaPiIIc and premature 
termination, missense mutations, intronic deletions, and nucleotide changes in a 
putative splice site  [21-22]. Inheritance follows an autosomal recessive pattern 
[21-22]. Some compound heterozygous patients carrying two different missense 
mutations were also identified [21]. However, carriers with only one allele 
mutated show normal phosphate balance and excretion but borderline or 
elevated renal calcium excretion [21-22]. 
 Since NAPI-IIc mutations are associated with a severe renal phosphate 
leak, NAPI-IIc may have a more important role in human kidney function than in 
rodents. NAPI-IIc function in man remains important during adulthood in contrast 
to rodents where NaPi-IIc may play an important role only during growth [11]. 
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Accordingly, two mouse models of Slc34a3 deficiency show only mild 
hypercalcuria without hyperphosphaturia or even no symptoms in the case of a 
kidney-specific gene deletion [58-59]. 
 
SLC9A3R1 (NHERF1): Na+/H+ exchanger regulating factor 1: 
hypophosphatemic nephrolithiasis/osteoporosis-2 (NPHLOP2) 
 NHERF1 mutations were detected in eight patients with mildly reduced 
TmP/GFR, slightly lower serum phosphate levels, nephrolithiasis in four out of 
eight patients, lower bone mineral density in one patient, normal to low PTH and 
calcium values and 1,25(OH)2D3 just above the normal range in all patients. Four 
NHERF1 mutations (E68A, L110V, R153Q, E225K) were found. All patients were 
heterozygous [60-61]. The mechanisms by which mutant NHERF1 may cause 
phosphaturia may be site-specific. In the case of the L110V, R153Q and E225K 
mutations, PTH and cAMP dependent inhibition of phosphate transport may be 
increased, whereas the E68A mutation may reduce the stability of the NaPiIIa 
transporter in the plasma membrane leading in all cases to lower transport 
activities [60-61].  
 
DEFECTS IN RENAL PHOSPHATE HANDLING SECONDARY TO 
EXTRARENAL INHERITED DEFECTS 
 
Fibroblast Growth Factor 23 (FGF23) 
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 FGF23 is primarily expressed in osteocytes [62-64]. Synthesis and release 
of FGF23 from bone are increased during hyperphosphatemia or high intake of 
phosphate [9, 65]. The major functions of FGF23 are the inhibition of renal 
phosphate reabsorption by downregulation of NAPI-IIa and NAPI-IIc expression 
and activity and by reducing the synthesis of active vitamin D3 through lowering 
expression of the renal CYP27B1 (1,25-alpha hydroxylase) and increasing 
CYP24A1 (1,24,25 hydroxylase). Lower concentrations of vitamin D3 decrease 
intestinal phosphate absorption. In addition, FGF23 suppresses PTH secretion. 
The effects of FGF23 on phosphate homeostasis are mediated by FGFR1c and 
FGFR4 receptors and require klotho as an obligatory co-ligand converting the 
low affinity receptors into high affinity FGF23 receptors [9, 66].  
 Synthesis of FGF23 in osteocytes is regulated a number of factors 
including including PTH, 1,25 vitamin D3 and a cascade of proteins consisting of 
PHEX, 7B2/PC2, BMP1 and DMP1. PTH and 1,25 vitamin D3 transcriptionaly 
stimulate FGF23 production by mechanisms involving PKA/Wnt and the VDR 
receptor, respectively [67-68]. Activation of this cascade increases proteolytic 
processing of DMP1 into N- and C-terminal fragments, from which the latest one 
is proposed to blunt the transcription of FGF23 (for review see: [69]).  
 FGF23 is degraded by C-terminal cleavage most likely by subtilisin-like 
proprotein convertases  [70]. FGF23 possesses a recognition site for cleavage by 
subtilisin-like proprotein convertases consisting of a RXXR motif at position 176. 
A recent report suggested that the PC2 propotein convertase, complexed with its 
chaperon 7B2, may mediate this process [71]. 
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FGF23 activating mutations: Autosomal dominant hypophosphatemic 
rickets (ADHR) 
  Autosomal dominant hypophosphatemic rickets (OMIM # 193100) 
is characterized by rickets, hypophosphatemia, hyperphosphaturia, fatigue, bone 
pain, lower bone deformities in face of inappropriately low or normal vitamin D3 
levels. ADHR is caused by mutations destroying the RXXR cleavage 
motifmentioned above, causing excessive levels of intact FGF23 [72]. Similarly, 
injection of mice withwildtype Fgf23 or Fgf23R179Q caused ADHR like symptoms 
in mice. Mutant Fgf23 caused hypophosphatemia, hyperphosphaturia, reduced 
intestinal phosphate absorption and suppressed serum vitamin D3 levels. In 
serum, high levels of mutant Fgf23 were detected whereas wildtype Fgf23 was 
degraded [73]. Transgenic mice for Fgf23R176Q display typical ADHR symptoms 
and show signs of secondary hyperparathyroidism [74]. Thus, ADHR is caused 
by mutations in a motif important for cleavage and degradation of FGF23 
resulting in excessive FGF23 signaling.          
 
Loss of function FGF23 mutations: familial tumoral calcinosis 
 Familial tumoral calcinosis (FTC, OMIM # 211900) is the mirror image of 
phosphate wasting diseases such as ADHR, TIO, and XLH. FTC is characterized 
by hyperphosphatemia, reduced renal phosphate excretion, ectopic 
calcifications, and inappropriately normal or elevated 1,25 (OH2) vitamin D3 
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levels. In a subset of FTC patients a homozygous 211A-G transition in the 
FGF23 gene was identified, resulting in the substitution at an evolutionarily 
conserved serine to glycine (S71G) [75]. This mutation may cause loss of 
function [75]. Patients have abnormally low FGF23 plasma concentrations. 
Mutant FGF23 protein expressed in vitro, was not secreted and retained 
intracellularly [75].  
 
Fibrous Dysplasia (McCune-Albright syndrome) 
Fibrous dysplasia (FD, OMIM #174800) is caused by non-inherited genetic 
somatic activating missense mutations in the α-subunit of the stimulatory G 
protein, Gs [76-77]. FD is characterized by abnormalities in bone (monostotic or 
polyostotic fibrous dysplasia), in skin (pigmentation), and in the endocrine system 
(thyrotoxicosis, pituitary gigantism, and Cushing syndrome). The severity of 
disease and particularly the association with skin and endocrine symptoms 
shows a wide variability. Renal phosphate wasting is detected in about 50 % of 
patients [78]. FGF23 levels are elevated and caused by a large mass of FGF23 
producing cells in fibrous bone lesions. Abnormal high FGF23 levels are caused 
by an increase in FGF23 producing cells but not by abnormal production of 
FGF23 per se [62, 79]. 
 
Klotho: familial tumoral calcinosis and hypophosphatemic rickets with 
hyperparathyrodism 
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 Mutations in the alpha-klotho (KL) gene can be another reason for familial 
tumoral calcinosis besides mutations in GALNT3 or loss-of-function mutations in 
FGF23. A single patient with a missense mutation was identified [80]. The 
mutation is predicted to affect the glucosidase domain of klotho which is involved 
in the regulation of TRPV5 calcium channels [81]. Moreover, reduced expression 
and glycosylation of klotho was demonstrated impairing the ability to interact with 
FGF23 and the FGF1R receptor. Accordingly, the patient had 
hyperphosphatemia, increased vitamin D3 and PTH levels and ectopic 
calcifications of vessels.  
 The mirror image was described in another single case of a balanced 
translocation between chromosome 13 and 9 at a position on chromosome 13 
adjacent to the alpha klotho gene. The translocation massively increased 
circulating klotho levels leading to hypophosphatemia, hyperphosphaturia, 
hypercalcemia, elevated PTH and FGF23, and low vitamin D3 [82]. The elevated 
FGF23 levels may be explained by a feedback loop by which circulating alpha-
klotho stimulates bone FGF23 expression [83]. 
  
Dentin matrix protein 1 (DMP1): Autosomal recessive hypophosphatemic 
rickets (ARHR) 
Patients with mutations in DMP1 suffer from hypophosphatemia due to 
hyperphosphaturia with inappropriately normal levels of 1,25-(OH)2 vitamin D3 
[84-85].  DMP1 belongs to the large SIBLING family (small integrin-binding 
ligand, N-linked glycoproteins) of extracellular matrix proteins and is mainly co-
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expressed with FGF23 in bone. The similar phenotype of patients with X-linked 
hypophosphatemia (XLH) and autosomal recessive hypophosphatemia with 
rickets (ARHR) suggested a link to FGF23. Indeed, in patients with loss of intact 
DMP1, FGF23 levels in serum were normal or elevated [84-85]. DMP1 (in 
particular the C-terminal fragment) blocks the transcription of FGF23; therefore, 
its absence may result in the release of this negative control leading to higher 
FGF23 production. The hypophosphatemia in DMP1 deficient patients causes 
severe rickets in children or osteomalacia in adults [84-85] which is characterized 
by abnormal amounts of osteoid indicating defective mineralization and 
maturation of bone [85]. Similarly a mouse model deficient for DMP1 shows 
hypophosphatemia, hyperphosphaturia, rickets, retarded skeletal growth with 
abnormal mineralization, disturbed lacunocanicular organization, and defective 
osteoblast to osteocyte differentiation [85].  
 
Tumor-induced osteomalacia (TIO) 
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome 
mostly associated with mesenchymal tumors releasing (a) phosphaturic factor(s). 
Symptoms include renal phosphate wasting causing hypophosphatemia, 
osteomalacia, and abnormal vitamin D metabolism [86]. Surgical removal of the 
tumor reverses symptoms. In contrast to syndromes of hyperparathyroidism or 
humoral hypercalcemia of malignancy, the plasma concentrations of calcium, 
PTH, and PTH related protein (PTHrp) are in the normal range. Several proteins, 
such as FGF23, sFRP4, FGF-7, and MEPE, have been identified that are 
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produced and secreted from tumors from patients with TIO. Some of these 
proteins have been shown to regulate phosphate transport in vitro and/or in vivo.  
Secreted frizzled-related protein-4 (sFRP-4) is highly upregulated in tumor 
tissue from patients with renal phosphate wasting [87] and inhibits phosphate 
transport in the renal OK cell line as well as in vivo [87-88]. However, mice 
lacking sfrp4 do not show any abnormalities of systemic phosphate balance [89]. 
Thus, the relevance of sFRP4 for phosphate homeostasis remains to be further 
clarified. 
 
Matrix extracellular phospho-glycoprotein (MEPE): oncogenic 
hypophosphatemia (OHO) 
MEPE, a glycosylated protein of about 60 kDa, was initially cloned from 
tumor tissue obtained from a patient with oncogenic hypophosphatemia (OHO) 
[90]. Bone cells (osteoblasts, osteocytes and odontoblasts) are the major source 
of MEPE. MEPE like DMP1 is another member of the SIBLING family of 
extracellular matrix proteins involved in bone regulation. Injection of MEPE into 
intact mice results in hypophosphatemia, hyperphosphaturia and mild increases 
in circulating 1,25 (OH)2 vitamin D3 levels [91]. Moreover, implantation of MEPE 
producing CHO cells into nude mice caused renal phosphate wasting, whereas 
MEPE deficient mice have higher bone density [92]. The interactions between 
MEPE and other hormones regulating phosphate homeostasis and handling 
require more investigation.  
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PHEX: X-linked hypophosphatemic rickets (XLH) 
 X-linked hypophosphatemic rickets (XLH)(OMIM #307800) is the most 
common heritable form of rickets with a prevalence of about 1 in 20.000. The 
disease is characterized by hypophosphatemia due to excessive renal phosphate 
wasting leading to rickets, lower extremities deformity, short stature, bone and 
joint pain, enthesopathy, and dental abscesses. Vitamin D3 levels are 
inappropriately normal or even low [93]. The disorder is inherited in a dominant 
manner. Positional cloning identified the PHEX gene (PHosphate regulating gene 
with homology to Endopeptidases on the X chromosome) in XLH patients [93]. 
Several mouse models of XLH are available: Hyp, Gy, and Ska1 mice resembling 
XLH and which were later shown to have mutations in the mouse Phex 
homologue [94-96]. The X-linked Hyp mouse model demonstrates a defect in 
proximal tubular phosphate absorption, decreased expression of NaPi-IIa and 
NaPi-IIc [97-99]. Serum FGF23 levels are highly elevated in XLH patients [100]. 
Crossing of hypophosphatemic Hyp mice with hyperphosphatemic Fgf23 
deficient mice produced hyperphosphatemic mice that showed exactly the same 
phenotype as Fgf23 null mice, indicating that both mutations affect the same 
system and that FGF23 may act downstream of PHEX [101]. Observations in 
Hyp and FGF23 null mice indicate that PHEX and FGF23 may regulate each 
others expression levels and that loss of PHEX may lead to higher expression 
levels of FGF23 [63, 65].  Although originally proposed, PHEX seems not to 
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mediate direct cleaving of FGF23 [63, 70]. Instead, PHEX may activate the PC2 
proprotein convertase by promoting the transcription of its 7B2 chaperon [71]. 
Transfection of osteoblast with 7B2.PC2 promoted cleavage of FGF23 whereas 
depletion of 7B2 mRNA reduced FGF23 cleavage and increased its transcription. 
The activated FGF23 transcription seems to result from an impaired proteolytic 
processing of DMP1 (see above). In agreement with this model, the mRNA levels 
of 7B2 are reduced in bones from Hyp mice [71].  
 
UDP-N-acetyl-α-D galactosamine:polypeptide N-acetyl-
galactosaminyltransferase (GALNT3): Familial tumoral calcinosis 
Homozygous loss of function mutations of the UDP-N-acetyl−α-D 
galactosamine:polypeptide N-acetyl-galactosaminyltransferase (GALNT3), a 
glycosyltransferase involved in mucin-type O-glycosylation,  underlie also familial 
tumoral calcinosis (FTC, OMIM # 211900) [102-103]. However, patients carrying 
only one mutated allele appear to have also mild symptoms, leading to the initial 
description of FTC as an autosomal dominant disease [104]. Because 
inactivating mutations in FGF23 also cause FTC and FGF23 has some O-
glycosylation sites within the subtilisin-recognition sites, it had been speculated 
that GALNT3 is critical for FGF23 gylcosylation and full function. Accordingly, in 
vitro secretion of FGF23 from CHO cells deficient in O-glycosylation is impaired 
and cotransfection of GALNT3 markedly increases O-glycosylation and secretion 
of FGF23. Thus, GALNT3 may play an important role in FGF23 secretion by 
mediating its O-glycosylation [105]. This function may also explain how loss of 
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function mutations in either FGF23 or GALNT3 can produce the same disease, 
FTC. 
 
Fibroblast Growth Factor Receptor 1 (FGFR1): Osteoglophonic dysplasia 
Osteoglophonic dysplasia (OMIM #166250) is caused by mutations in the 
fibroblast growth factor receptor 1 (FGFR1) that result in a gain-of-function and 
activation of the receptor [106]. Patients suffer from craniosynostosis, prominent 
supraorbital ridge, and depressed nasal bridge, as well as from rhizomelic 
dwarfism and nonossifying bone lesions. Several missense mutations in the 
FGFR1 gene were identified in 4 patients. Three patients were 
hypophosphatemic due to massive renal phosphate wasting [106]. One patient 
had inappropriately high FGF23 levels, two patients had high 1,25-(OH)2 vitamin 
D3 levels. As two related patients carried the Y372C FGFR1 mutation. The 
activity of the mutant receptor was highly increased suggesting that overactivity 
of the FGF1 receptor is responsible for this disease [106]. The FGFR1 receptor 
mediates the downregulation of NAPI-IIa and NAPI-IIc by FGF23, whereas the 
effects of FGF23 on vitamin D3 metabolism may involve the FGFR4 receptor [66].  
 
FAM20C: Raine syndrome (osteosclerotic bone dysplasia) 
 Raine syndrome is caused by mutations in the protein kinase FAM20C 
which resides in the Golgi apparatus and is secreted [107-108]. Patients develop 
generalized higher bone density with characteristic changes and enhancement of 
the ossification of the skull, cerebral calcification, and in some case hypoplastic 
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lungs. The disease is often lethal in the first weeks after birth but patients with 
longer survival reaching into puberty have been described. The renal phenotype 
of patients with Raine syndrome has not been reported in detail. Targets 
phosphorylated by FAM20C are casein, osteoprotegerin (OPN), DMP1, and 
MEPE, members of the SIBLINGs family. In Fam20c deficient mice, 
hypophosphatemic rickets was observed possibly due to dysregulation of FGF23 
(which is very high) due to lack of DMP1 phosphorylation [109]. 
 
CONCLUSION AND OUTLOOK 
Renal and extrarenal control of systemic phosphate homeostasis requires 
a complicated network of regulatory factors, phosphate transporters in kidney, 
intestine, and bone, and intracellular protein-protein interactions. Rare human 
genetic disorders and mouse genetics have greatly contributed to our current 
understanding of (renal) phosphate homeostasis. Importantly, population based 
genome wide association studies identified SLC34A1 and FGF23 as important 
determinants of plasma phosphate levels [110]. Moreover, the highly elevated 
FGF23 levels in patients with various types of CKD and the potential link 
between FGF23 and cardiovascular disease in these patients underlines even 
further the biological importance of this homeostatic system for health and 
disease. Nevertheless, our understanding of key elements of this system is 
incomplete and we require deeper insights how organs and cells sense 
phosphate and how changes in systemic phosphate levels can trigger disease. 
The identification of key players through genetics may also pave the way for 
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therapies targeting disturbed phosphate balance in both rare inherited disorders 
as well as in more common diseases such as CKD. 
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Table 1 
Summary of known factors influencing renal phosphate excretion   
For explanation and references see text. 
 
Table 2 
Summary of disorders affecting renal phosphate handling 
For explanation and references see text. 
 
 
Table 3 
Factors affecting renal phosphate handling due to acquired syndromes 
For explanation and references see text. 
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Table 1 
 
Factors affecting phosphate reabsorption in the proximal tubule 
 
 
Factors that decrease  
Pi reabsorption 
Factors that increase  
Pi reabsorption 
Acidosis 
High dietary Pi intake 
Parathyroid hormone/ cAMP 
Atrial Natriuretic Peptide/ cGMP 
Glucocorticoids 
Dopamine 
Fibroblast growth factor 23 
MEPE 
Frizzled related protein 4  
Alkalosis 
Low dietary Pi intake 
Parathyroidectomy 
Thyroid hormone 
1α,25(OH)2D3 
Growth hormone(s)  
Insulin-like growth factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
Genes/ diseases causing altered renal phosphate handling 
 
Gene Chromosome/ 
OMIM 
Disease name Major symptoms Inheritance Tissue 
distribution of 
protein 
SLC34A1 
(NaPiIIa) 
5q35 
OMIM#612286 
 
 
OMIM#613388 
hypophosphatemic 
nephrolithiasis/osteoporosis-
1 (NPHLOP1) 
 
Fanconi renotubular 
syndrome-2 (FRTS2) 
Hypophosphatemia, 
urolithiasis, 
osteoporosis ? 
Fanconi-like 
syndrome 
 
Autosomal 
dominant  
 
 
Autosomal 
recessive 
Kidney (proximal 
tubule) 
SLC34A3 
(NaPiIIc) 
9q34 
OMIM#241530 
Hereditary 
hypophosphatemic rickets 
with hypercalciuria (HHRH) 
Hypophosphatemia, 
hyperphosphaturia, 
rickets, 
Hypercalciuria 
Normal-low FGF23, 
high 1,25-D3 
Autosomal 
recessive 
Kidney (proximal 
tubule) 
SLC9A3R1 
(NHERF1) 
17q25.1 
OMIM#612287 
hypophosphatemic 
nephrolithiasis/osteoporosis-
2 (NPHLOP2) 
Hypophosphatemia 
Hyperphosphaturia 
Normal-low PTH 
Mildy elevated 1,25-
D3 
Nephrolithiasis 
Autosomal 
dominant 
Kidney, intestine 
FGF23 12p13.3 
OMIM#193100 
 
 
 
- Autosomal dominant 
hypophosphatemic rickets 
(ADHR) 
 
- Familial tumoral calcinosis 
Hyperphosphaturia 
Hypophosphatemia 
Rickets/osteomalacia 
Normal 1,25-D3 
High FGF23 
Autosomal 
dominant 
Mainly bone 
OMIM#211900 
 
(FTC) 
Klotho 13q13.1  
OMIM#211900 
 
 
 
 
 
 
 
Familial tumoral calcinosis 
 
 
 
 
 
 
Hypophosphatemic rickets 
with hyperparathyroidism 
Hyperphosphatemia 
hypercalcemia 
Heterotopic 
calcifications 
high intact FGF23 
high PTH 
 
Hypophosphatemia 
Hyperphosphaturia 
High FGF23 
High PTH 
Autosomal 
recessive 
 
 
 
 
 
Translocation, 
dominant 
Kidney, 
parathyroid 
gland, brain 
PHEX Xp22.2-p22.1 
OMIM#307800 
X-linked hypophosphatemia 
(XLH) 
Hyperphosphaturia 
Hypophosphatemia 
Rickets/osteomalacia 
Normal vit. D 
High FGF23 
X-linked Mainly bone 
GALNT3 2q24-q31 
OMIM#211900 
Familial tumoral calcinosis 
(FTC) 
Hyperphosphatemia 
heterotopic 
calcification 
Autosomal 
recessive 
Pancreas, testis 
GNAS1 20q13.2 
OMIM#174800 
Fibrous dysplasia 
(McCune-Albright 
syndrome) 
Hyperphosphaturia, 
high FGF-23 levels, 
polyostotic fibrous 
dysplasia, 
pigmentation, 
thyrotoxicosis, 
Cushing 
Autosomal 
dominant, 
mosaicism 
ubiquitous 
FAM20c 7p22.3 
OMIM#259775 
Raine syndrome 
Osteosclerotic bone 
dysplasia 
Increased bone 
density, periostal 
bone growth 
Skull deformation 
Autosomal 
recessive 
Bone, 
kidney,mammary 
gland, and 
others 
FGFR1 8p11.2-p11.1 
OMIM#166250 
Osteoglophonic dysplasia Hypophosphatemia 
Hyperphosphaturia 
Craniosynostosis 
Autosomal 
dominant ? 
Ubiquitous, 
bone, kidney 
DMP1 4q21 
OMIM#241520 
Autosomal recessive 
hypophosphatemic rickets 
(ARHR) 
Autosomal recessive 
hypophosphatemia (ARHP) 
Hypophosphatemia 
Hyperphosphaturia 
Rickets, 
osteomalacia 
Autosomal 
recessive 
Ubiquitous, 
Bone, heart, 
kidney 
 
 
 
 
Table 3: Acquired forms of renal phosphate wasting 
 
 
Gene/factor Chromosome/OMIM Disease Symptoms Occurrence Tissue 
distribution 
sFRP4 7p14-p13 
OMIM606570 
Tumor 
induced 
osteomalacia 
(TIO) 
Hypophosphatemia 
Hyperphosphaturia 
Osteomalacia 
Spontaneous ? Tumor 
bone 
FGF7 15q15-q21.1 
OMIM148180 
Tumor 
induced 
osteomalacia 
(TIO) 
Hypophosphatemia 
Hyperphosphaturia 
Osteomalacia 
Spontaneous ? Tumor 
MEPE 4q21.1 
OMIM605912 
Tumor 
induced 
osteomalacia 
(TIO) 
Hypophosphatemia 
Hyperphosphaturia 
Osteomalacia 
 
Spontaneous ? Tumor, bone 
 
